Pharm-Olam International Completes Enrollment of 700 Patient Global Pivotal Phase III Clinical Trial for Metastatic Breast Cancer

Houston, TX, November 25, 2005 --(PR.com)-- HOUSTON, TEXAS – November 27, 2005 – Pharm-Olam International Ltd. (POI) has completed enrollment of a 700 patient pivotal trial for the treatment of metastatic and recurrent breast cancer. Enrollment of the Phase III clinical trial was achieved on schedule in just 18 months and includes more than 100 clinical sites in 17 countries around the world. "Having our own local employees across the globe, especially in the emerging markets, allows POI to meet the requirements for sponsors that require a large number of patients in a short timeframe," said Iain Gordon, Director of Global Business Development.

Pharm-Olam International Ltd. provided full services to the sponsor, including translations, CRF design & printing, sites selections, investigator meetings, ethics and regulatory approvals, import/export licenses, drug labeling and distribution, project management, monitoring, pharmacovigilence, data management and report writing.

Pharm-Olam International Ltd. is a multi-national, contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. Pharm-Olam has been conducting clinical trials for over 10 years with our own local employees in more than 20 countries.

For further information on Pharm-Olam’s role in this study, a reference from the sponsor, or for general inquiries please contact Iain Gordon at igordon@pharm-olam.com.

###